BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 268
- Registration Number
- NCT04895696
- Locations
- 🇨🇳
Local Institution - 0196, Baoding, Hebei, China
🇺🇸Private Practice - Dr. Jefrey Lieberman, Decatur, Georgia, United States
🇺🇸Local Institution - 0100, Birmingham, Alabama, United States
A Study to Determine the Safety, Drug Levels and Drug Effects of BMS-986196 and Food and Formulation Effects on Relative Absorption Healthy Participants
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 102
- Registration Number
- NCT04882150
- Locations
- 🇺🇸
Local Institution - 0002, Salt Lake City, Utah, United States
A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
- Conditions
- Renal Allograft Recipients
- Interventions
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 102
- Registration Number
- NCT04877288
- Locations
- 🇺🇸
Local Institution - 0022, Hollywood, Florida, United States
🇺🇸Local Institution - 0045, Miami, Florida, United States
🇺🇸Local Institution - 0049, Atlanta, Georgia, United States
A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 67
- Registration Number
- NCT04877990
- Locations
- 🇺🇸
Local Institution - 0036, Shreveport, Louisiana, United States
🇯🇵Local Institution - 0026, Bunkyo-ku, Tokyo, Japan
🇺🇸Local Institution - 0002, Wyoming, Michigan, United States
A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
- Conditions
- Lupus Erythematosus, DiscoidLupus Erythematosus, Subacute Cutaneous
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 75
- Registration Number
- NCT04857034
- Locations
- 🇲🇽
Local Institution - 0071, Mexico City, Mexico
🇨🇳Local Institution - 0022, Taipei, Taiwan
🇺🇸Local Institution - 0059, Saint Louis, Missouri, United States
A Study of Anticoagulation Treatment Patterns and Outcomes of Participants Hospitalized With Coronavirus Disease 2019 (COVID-19) in Japan
- Conditions
- COVID-19
- First Posted Date
- 2021-04-02
- Last Posted Date
- 2022-05-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 9282
- Registration Number
- NCT04828772
- Locations
- 🇯🇵
Medical Data Vision, Tokyo, Japan
🇯🇵Local Institution, Minato-ku, Tokyo, Japan
A Study of Treatment Patterns and Clinical Outcomes of Psoriasis in Japan
- Conditions
- Psoriasis
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2022-06-03
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 114
- Registration Number
- NCT04826536
- Locations
- 🇯🇵
Local Institution, Minato-ku, Tokyo, Japan
A Study to Assess Safety of Nivolumab in Routine Oncology Practice in China
- Conditions
- Non-Small Cell Lung CancerSquamous Cell Carcinoma of Head and Neck
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 3102
- Registration Number
- NCT04825873
- Locations
- 🇨🇳
Local Institution, Shanghai, Shanghai, China
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
- Conditions
- Myelofibrosis
- Interventions
- First Posted Date
- 2021-03-25
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 216
- Registration Number
- NCT04817007
- Locations
- 🇫🇷
Local Institution - 0010, Villejuif, France
🇺🇸Local Institution - 0069, Newport Beach, California, United States
🇺🇸Local Institution - 0090, Lake Mary, Florida, United States
A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread
- Conditions
- Clear Cell Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 632
- Registration Number
- NCT04810078
- Locations
- 🇷🇴
Local Institution - 0040, Cluj-Napoca, Romania
🇷🇴Local Institution - 0016, Craiova, Romania
🇷🇴Local Institution - 0002, Cluj-Napoca, Romania